Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Disopyramide phosphate
Drug ID BADD_D00694
Description A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Indications and Usage For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias. It is a Class Ia antiarrhythmic drug.
Marketing Status Prescription; Discontinued
ATC Code C01BA03
DrugBank ID DB00280
KEGG ID D00637
MeSH ID D004206
PubChem ID 30928
TTD Drug ID D0M4YC
NDC Product Code 42291-234; 0093-3127; 0093-3129; 68259-1304; 59762-0400; 0025-2752; 55512-0004; 0025-2732; 59762-0386; 42291-235; 51862-095; 0025-2762; 51862-096; 0025-2742; 51014-7863
Synonyms Disopyramide | Diisopyramide | Disopyramide Phosphate | Disopyramide Phosphate (1:1) | Disopyramide Phosphate (1:1), (+-)-Isomer | Disopyramide Phosphate (1:1), (R)-Isomer | Disopyramide Phosphate (1:1), (S)-Isomer | Disopyramide, (+-)-Isomer | Disopyramide, (R)-Isomer | Disopyramide, (S)-Isomer | Disopyramide, D-Tartrate (1:1), (S)-Isomer | Disopyramide, L-Tartrate (1:1), (R)-Isomer | Disopyramide, L-Tartrate (1:1), (S)-Isomer | Disopyramide, L-Tartrate (1:2), (+-)-Isomer | Disopyramide, L-Tartrate, (S)-isomer | Norpace | Palpitin | Palpitine | Rhythmodan | Ritmilen | Rythmilen | SC-13957 | SC 13957 | SC13957 | Disopyramide Monohydrochloride
Chemical Information
Molecular Formula C21H32N3O5P
CAS Registry Number 22059-60-5
SMILES CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C.OP(=O)(O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
Sudden cardiac deathPotassium voltage-gated channel subfamily E member 1P15382Not AvailableNot Available
Sudden cardiac deathPotassium voltage-gated channel subfamily H member 2Q12809T20251Not Available
Sudden cardiac deathPotassium voltage-gated channel subfamily KQT member 1P51787T49526Not Available
Sudden cardiac deathSodium channel protein type 5 subunit alphaQ14524T39716Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Acute psychosis19.03.01.001--Not Available
Agranulocytosis01.02.03.001--Not Available
Atrioventricular block02.03.01.002--Not Available
Blood cholesterol increased13.12.01.002--
Blood creatinine increased13.13.01.004--
Blood triglycerides increased13.12.03.001--Not Available
Blood urea increased13.13.01.006--Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Constipation07.02.02.001--
Depression19.15.01.001--
Diarrhoea07.02.01.001--
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.003--
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dry throat22.02.05.004; 07.06.01.005--Not Available
Dyspnoea22.02.01.004; 02.01.03.002--
Dysuria20.02.02.002--
Fatigue08.01.01.002--
Gynaecomastia21.05.04.003; 05.05.02.003--
Haematocrit decreased13.01.05.001--Not Available
Haemoglobin decreased13.01.05.003--Not Available
Headache17.14.01.001--
Hypoaesthesia17.02.06.023--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypokalaemia14.05.03.002--
Hypotension24.06.03.002--
Insomnia19.02.01.002; 17.15.03.002--
Malaise08.01.01.003--
Micturition urgency20.02.02.006--
The 1th Page    1 2    Next   Last    Total 2 Pages